STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
STREAM is inviting applications for a postdoctoral research fellow (PDF) with a background in systematic review, clinical trials, or ethics. Special consideration will be given to candidates knowledgeable in research ethics, statistics, or meta-science.
The project will examine how risk, benefit, burdens, and clinical hypotheses evolve as new drugs are developed- and whether there are ways to improve efficiencies in clinical development.
See job posting for more details.
Jonathan Kimmelman gives his take on underreporting of adverse events in trial reports: Des effets secondaires des médicaments restent absents des publications scientifiques in Le Devoir
Jonathan Kimmelman quoted in the Portland Press Herald
Jonathan Kimmelman quoted in CMAJ
Jonathan Kimmelman's work for the new International Society for Stem Cell Research guidelines featured in Nature!
Work of STREAM profiled in Nature Reviews Clinical Oncology
Kimmelman J. Is Participation in Cancer Phase I Trials Really Therapeutic? Journal of Clinical Oncology. 2016.
London AJ, Kimmelman J. Accelerated Drug Approval and Health Inequality. JAMA Intern Med. 2016. DOI:10.1001/jamainternmed.2016.2534
Mattina J, MacKinnon N, Henderson VC, Fergusson D, Kimmelman J. Design and Reporting of Targeted Anti-Cancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy. Cancer Res 2016; DOI: 10.1158/0008-5472.CAN-15-3455 [Epub ahead of print]
Grankvist H and Kimmelman J. How do researchers decide early clinical trials? Medicine, Health Care and Philosophy 2016.
Kimmelman J, Henderson VC. Assessing risk/benefit for trials using preclinical evidence: a proposal. Journal of Medical Ethics 2015; DOI: doi:10.1136/medethics-2015-102882
Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, Hey SP, London AJ, Kimmelman J. Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib JNCI 2015; DOI: 10.1093/jnci/djv292